Skin Rash Occurring with Olanzapine Pamoate,but not with Oral Olanzapine,in a Male with Juvenile Idiopathic Arthritis

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4thText RevisionWashington, DC: American Psychiatric Association, 2000.

Benito-León J , Mitchell AJ . Guillain-Barré-like syndrome associated with olanzapine hypersensitivity reaction. Clin Neuropharmacol, 28:150–151. 2005.

Chang HY , Ridky TW , Kimball AB , Hughes E , Oro AE . Eruptive xanthomas associated with olanzapine use. Arch Dermatol, 139:1045–1048. 2003.

Christen S , Gueissaz F , Anex R , Zullino DF . Acute generalized exanthematous pustulosis induced by olanzapine. Acta Medica (Hradec Králové), 49:75–76. 2006.

Chue P , Chue J . A review of olanzapine pamoate. Expert Opin Pharmacother, 13:1661–1670. 2012.

Detke HC , Zhao F , Witte MM . Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: An insight from effect size comparison with historical oral data. BMC Psychiatry, 12,51 2012.

Duggal MK , Singh A , Arunab H , Lolis JD , Guzik HJ . Olanzapine-induced vasculitis. Am J Geriatr Pharmacother, 3:21–24. 2005.

Espada G . Juvenile idiopathic arthritis. Part 1: Diagnosis, pathogenesis and clinical manifestations [in Spanish] Arch Argent Pediatr, 107:441–448. 2009.

Frampton JE . Olanzapine long-acting injection: A review of its use in the treatment of schizophrenia. Drugs, 70:2289–2313. 2010.

Huang JL . New advances in juvenile idiopathic arthritis. Chang Gung Med J, 35:1–14. 2012.

Jhirwal OP , Parsad D , Basu D . Skin hyperpigmentation induced by olanzapine, a novel antipsychotic agent. Int J Dermatol, 43:778–779. 2004.

Kane JM , Detke HC , Naber D , Sethuraman G , Lin DY , Bergstrom RF , McDonnell D . Olanzapine long–acting injection: A 24 week, randomized, double-blind trial of maintenance treatment in patient with schizophrenia. Am J Psychiatry, 167:181–189. 2010.

Lowney AC , McAleer MA , Bourke J . Occupational allergic contact dermatitis to olanzapine. Contact Dermatitis, 62:123–124. 2010.

Naranjo CA , Busto U , Sellers EM , Sandor P , Ruiz I , Roberts EA , Janecek E , Domecq C , Greenblatt DJ . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 30:239–245. 1981.

Papaioannides D , Sinapidis D , Korantzopoulos P , Charalabopoulos K . A case of cutaneous vasculitis associated with olanzapine. Int J Low Extrem Wounds, 5:116–117. 2006.

Perry R , Wolberg J , Dicrescento S . Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient tolerant of oral risperidone. Am J Health Syst Pharm, 69:40–43. 2012.

Prevost P , Bédry R , Lacoste D , Ezzedine K , Haramburu F , Milpied B . Hypersensitivity syndrome with olanzapine confirmed by patch tests. Eur J Dermatol, 22:126–127. 2011.

Rashid J , Wang R , Ramer SL . Atypical antipsychotics and seborrheic dermatitis: Three case reports. Pharmacopsychiatry, 40:103–106. 2007.

Raz A , Bergman R , Eilam O , Yungerman T , Hayek T . A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci, 321:156–158. 2001.

Reeves RR , Mack JE . Allergic reaction to depot risperidone but not to oral risperidone. J Clin Psychiatry, 66,949 2005.

Sinnott BP , Mazzone T . Tuberous xanthomas associated with olanzapine therapy and hypertriglyceridemia in the setting of a rare apolipoprotein E mutation. Endocr Pract, 12:183–187. 2006.